A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
This article was originally published in PharmAsia News
Executive Summary
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.
You may also be interested in...
Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary
SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out
Insider Analysis From Morrison & Foerster LLP: China’s Bolar Exemption - Beware of the Uncertainties of Its Reach And Scope (Part 1 of 2)
By Janet Xiao, Morrison & Foerster LLP, Palo Alto and Michael Vella, Morrison & Foerster LLP, Shangha
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.